US2012220532A1PendingUtilityA1

Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2

49
Individually held — no corporate assignee on recordPriority: Oct 9, 2003Filed: Nov 23, 2011Published: Aug 30, 2012
Est. expiryOct 9, 2023(expired)· nominal 20-yr term from priority
Inventors:Yigal M. Pinto
A61P 9/00A61P 9/12A61P 9/04G01N 33/6887G01N 2800/325G01N 2333/4724G01N 2800/321G01N 33/6893G01N 2800/50Y10S436/811G01N 33/9453G01N 2333/4704G01N 2333/4728
49
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a method for identifying a subject at risk of developing hypertensive end organ damage, such as and in particular heart failure, comprising: a) obtaining a biological sample of said subject; b) determining the level of at least one non-myocytal marker in said sample; c) comparing the level of said marker to a standard level; and d) determining whether the level of the marker is indicative of a risk for developing hypertensive end organ damage. The non-myocytical marker preferably is galectin-3 or thrombospondin-2.

Claims

exact text as granted — not AI-modified
1 - 12 . (canceled) 
     
     
         13 . A method of treating or preventing hypertensive end organ damage or complications of heart failure, comprising inhibiting galectin-3 in a subject. 
     
     
         14 . The method of  claim 13 , wherein the hypertensive end organ damage is heart failure. 
     
     
         15 . The method of  claim 13 , wherein the subject has cardiovascular disease. 
     
     
         16 . The method of  claim 13 , wherein the subject is identified as having elevated circulatory levels of galectin-3. 
     
     
         17 . The method of  claim 13 , wherein the subject is a human.

Join the waitlist — get patent alerts

Track US2012220532A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.